Quest Diagnostics, Inc. (DGX)

HEALTH CARE: HEALTH CARE SERVICES
SIC: SERVICES-MEDICAL LABORATORIES

500 PLAZA DRIVE SECAUCUS, NJ 07094

Quest Diagnostics is a provider of diagnostic testing, information and services. Co. is a provider of: clinical testing, which is generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples; and anatomic pathology services principally for the detection of cancer and are performed on tissues, such as biopsies, and other samples, such as human cells. Co.'s other operating segments include its non-clinical testing businesses and consist of its risk assessment services, clinical trials testing, healthcare information technology, and diagnostics products businesses.

Data as of 2020-11-22
Market Cap16.82 Billion Shares Outstanding134.766 Million Avg 30-day Volume1.208 Million
P/E Ratio15.4 Dividend Yield1.795 EPS8.09
Price/Sales2.012 Price cash flow ratio9.4 Price free cash flow ratio22.1
Book Value47.49 Price to Tangible Book-10.06 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.40241
BETA1.1827 52-week High/Low131.81 / 73.02 Stddev0.078567
View SEC Filings from DGX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 5 -60.0% 0 (0.0%) 2 (0.13%) -100.0%
Funds Holding: 730 729 0.14% 157 (10.32%) 155 (10.06%) 1.29%
13F shares: 115.931 Million 117.404 Million -1.25% 20.961 Million 24.008 Million -12.69%
% Ownership 86.3208 87.4176 -1.25% 15.6069 17.8761 -12.69%
New Positions: 90 125 -28.0% 29 42 -30.95%
Increased Positions 238 211 12.8% 45 44 2.27%
Closed Positions 75 85 -11.76% 24 28 -14.29%
Reduced Positions 265 287 -7.67% 62 53 16.98%
Total Calls 639.415 Thousand 883.319 Thousand -27.61% 145.5 Thousand 350.2 Thousand -58.45%
Total Puts 929.528 Thousand 460.62 Thousand 101.8% 323.8 Thousand 170.1 Thousand 90.36%
PUT/CALL Ratio 1.45 0.52 178.85% 2.23 0.49 355.1%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding DGX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DGX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

355.4 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

344.1 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WILENSKY GAIL R

  • Director
29,857 2020-11-24 2

STANZIONE DANIEL

  • Director
28,349 2020-11-23 2

DEPPE MICHAEL J VP, CORP. CONTROLLER & CAO

  • Officer
55,513 2020-10-21 6

RUSCKOWSKI STEPHEN H CHAIRMAN, CEO AND PRESIDENT

  • Officer
  • Director
237,747 2020-10-16 7

PREVOZNIK MICHAEL E SVP & GENERAL COUNSEL

  • Officer
45,261 2020-10-14 6

MENDEZ MANUEL O. SVP & CHIEF COMMERCIAL OFFICER

  • Officer
23,982 2020-10-06 3

RING TIMOTHY M

  • Director
0 2020-10-01 6

DOHERTY CATHERINE T. SVP, GROUP EXEC. CLIN. FRAN.

  • Officer
72,467 2020-09-02 5

GUINAN MARK EXECUTIVE VICE PRESIDENT & CFO

  • Officer
73,579 2020-06-08 5

PFEIFFER GARY M

  • Director
21,513 2020-05-19 1

MAIN TIMOTHY L

  • Director
19,588 2020-05-19 1

GREGG VICKY B

  • Director
13,844 2020-05-19 1

TORLEY HELEN

  • Director
4,897 2020-05-19 1

MORRISON DENISE M

  • Director
3,783 2020-05-19 1

LASSITER WRIGHT III

  • Director
1,882 2020-05-19 3

EGLINTON MANNER CARRIE SVP, ADVANCED DIAGNOSTICS

  • Officer
22,390 2020-04-27 6

DAVIS J. E. EVP, GENERAL DIAGNOSTICS

  • Officer
38,086 2020-03-16 6

CUNNINGHAM EVERETT SVP, COMMERCIAL

  • Officer
39,032 2019-03-01 0

KLUG ROBERT A VP, CORPORATE CONTROLLER

  • Officer
6,261 2019-03-01 0

BRITELL JENNE K

  • Director
14,479 2018-06-04 0

LEIDEN JEFFREY M

  • Director
6,000 2018-05-29 0

COHEN JON R SVP & GROUP EXEC. DIAG. SOL.

  • Officer
31,757 2018-03-08 0

ZIEGLER JOHN B

  • Director
16,557 2017-02-22 0

BALDWIN JOHN C MD

  • Director
12,949 2015-08-12 0

BONGIORNO THOMAS F VP AND CORPORATE CONTROLLER

  • Officer
15,002 2015-02-27 0

HAYDON JOHN B. SVP, OPERATIONS

  • Officer
19,890 2014-02-13 0

BUEHLER WILLIAM F

  • Director
26,225 2014-02-12 0

ORDONEZ KATHY SVP, DIAGNOSTIC SOLUTIONS

  • Officer
9,569 2013-03-31 0

HAGEMANN ROBERT SVP & CHIEF FINANCIAL OFFICER

  • Officer
162,520 2013-03-05 0

MOHAPATRA SURYA N CHAIRMAN, PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2012-04-30 0

MILLER JOAN ELIZABETH SVP-ONCOLOGY & NEUROLOGY SRVCS

  • Officer
90,279 2012-02-29 0

SIMMONS WAYNE R. VICE PRESIDENT, OPERATIONS

  • Officer
47,752 2011-06-16 0

GLAXOSMITHKLINE PLC

  • Director
  • 10% Owner
No longer subject to file 2011-01-31 0

HAGGERTY ROSANNE

  • Director
9,334 2010-05-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WILENSKY GAIL R - Director

2020-11-27 16:38:37 -0500 2020-11-24 S 6,111 $126.02 d 16,482 direct 1.3712 1.3712 2 0.0 1

WILENSKY GAIL R - Director

2020-11-27 16:38:37 -0500 2020-11-24 M 6,111 $57.67 a 22,593 direct 1.3712 1.3712 2 0.0 1

WILENSKY GAIL R - Director

2020-11-27 16:38:37 -0500 2020-11-24 M 6,111 $57.67 d 0 direct

STANZIONE DANIEL - Director

2020-11-24 16:31:08 -0500 2020-11-23 S 3,302 $126.46 d 30,649 direct yes 0.378 -1.2145 1.0858 4 -1.2145 6

STANZIONE DANIEL - Director

2020-11-24 16:31:08 -0500 2020-11-23 S 5,621 $125.73 d 33,951 direct yes 0.378 -1.2145 1.0858 4 -1.2145 6

STANZIONE DANIEL - Director

2020-11-24 16:31:08 -0500 2020-11-23 S 2,300 $127.45 d 28,349 direct yes 0.378 -1.2145 1.0858 4 -1.2145 6

DEPPE MICHAEL J - Officer VP, CORP. CONTROLLER & CAO

2020-10-23 16:42:24 -0400 2020-10-21 M 4,750 $56.82 d 0 direct yes

DEPPE MICHAEL J - Officer VP, CORP. CONTROLLER & CAO

2020-10-23 16:42:24 -0400 2020-10-21 M 5,700 $57.61 a 35,485 direct yes 2.2764 0.4183 2.2764 2 -1.7535 5

DEPPE MICHAEL J - Officer VP, CORP. CONTROLLER & CAO

2020-10-23 16:42:24 -0400 2020-10-21 S 4,750 $125.00 d 25,090 direct 2.2764 0.4183 2.2764 2 -1.7535 5

DEPPE MICHAEL J - Officer VP, CORP. CONTROLLER & CAO

2020-10-23 16:42:24 -0400 2020-10-21 M 4,750 $56.82 a 29,785 direct yes 2.2764 0.4183 2.2764 2 -1.7535 5

DEPPE MICHAEL J - Officer VP, CORP. CONTROLLER & CAO

2020-10-23 16:42:24 -0400 2020-10-21 M 5,700 $57.61 d 0 direct yes

DEPPE MICHAEL J - Officer VP, CORP. CONTROLLER & CAO

2020-10-23 16:42:24 -0400 2020-10-21 S 5,700 $125.00 d 29,785 direct 2.2764 0.4183 2.2764 2 -1.7535 5

RUSCKOWSKI STEPHEN H - Director - Officer CHAIRMAN, CEO AND PRESIDENT

2020-10-19 16:17:18 -0400 2020-10-16 S 291,997 $120.00 d 237,747 direct yes -0.3973 3.1057 0.8596 3.8355 13 -2.4327 15

RUSCKOWSKI STEPHEN H - Director - Officer CHAIRMAN, CEO AND PRESIDENT

2020-10-19 16:17:18 -0400 2020-10-16 M 291,997 $66.51 a 529,744 direct yes -0.3973 3.1057 0.8596 3.8355 13 -2.4327 15

RUSCKOWSKI STEPHEN H - Director - Officer CHAIRMAN, CEO AND PRESIDENT

2020-10-19 16:17:18 -0400 2020-10-16 M 291,997 $66.51 d 0 direct yes

PREVOZNIK MICHAEL E - Officer SVP & GENERAL COUNSEL

2020-10-15 16:45:48 -0400 2020-10-14 S 35,591 $119.00 d 40,087 direct 0.5241 5.7654 3.1448 6.5308 15 0.0 1

PREVOZNIK MICHAEL E - Officer SVP & GENERAL COUNSEL

2020-10-15 16:45:48 -0400 2020-10-14 M 35,591 $52.17 a 75,678 direct yes 0.5241 5.7654 3.1448 6.5308 15 0.0 1

PREVOZNIK MICHAEL E - Officer SVP & GENERAL COUNSEL

2020-10-15 16:45:48 -0400 2020-10-14 M 35,591 $52.17 d 0 direct yes

MENDEZ MANUEL O. - Officer SVP & CHIEF COMMERCIAL OFFICER

2020-10-07 16:35:50 -0400 2020-10-06 F 5,871 $114.01 d 23,982 direct 0.3354 1.5996 5.6158 10.1221 21 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments